Seres president and chief executive Eric Shaff
Seres quietly discloses it has once again altered plans in ulcerative colitis
A month after another setback in its plans to treat ulcerative colitis, Seres Therapeutics quietly disclosed it will not move forward with a Phase Ib …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
